Chronolife launches its connected T-Shirt manufacturing as well as key clinical trial across Europe
Paris (France), January 6th, 2019 – Chronolife, an artificial intelligence company specialized in digital health, announces the launch of the industrialization and production of its connected and washable T-shirt targeting pharma companies, insurance companies and preventive care service providers.
The company recently finalized the development of a washable T-shirt that continuously monitors and collects data on six physiological parameters (electrocardiogram, abdominal breathing, thoracic breathing, pulmonary impedance, physical activity and body temperature). All sensors and electronic components are fully integrated in the fabric of the T-shirt. It is comfortable and washable without the need to extract any electronic component before washing it. The biometrics data collected is transmitted through BlueTooth Low Energy (BTLE) to the user’s smartphone application for continuous data fusion and analysis. Events can be generated by comparing the measurements to an agreed profile, pattern and protocol.
The manufacturing of the Chronolife T-shirt has started so that the clinical trial of the entire end-to-end solution can be launched in the second half of 2019. The solution comprises of the T-Shirt, a smartphone application with HOTS algorithm, an accredited server and a Web interface. The CE marking and commercial release of the solution for remote monitoring and prevention is planned for April 2019. The T-Shirt and associated smartphone application is planned to be a healthcare-graded Class II CE-marking and FDA approved solution for RPM (Remote Patient Monitoring) as from summer 2019. It is planned to be a predictive solution for CHF (Chronic Heart Failure) by summer 2020 following the clinical trial currently launched in Europe.
The clinical trial in Europe will consist in approximately 500 plus heart failure patients from around 20 large hospitals based across France, Denmark and Germany. Patients will be equipped during hospital discharge following a cardiac decompensation. This clinical survey should last a year in Europe. The collected data would allow Chronolife to train and validate its patented algorithm HOTS for detection and prediction of chronic heart failure.
Chronolife is an artificial intelligence company specialized in digital health. Its patented technology is a unique neuromorphic algorithm called HOTS (Hierarchy Of even-based Time Surfaces), which analyses several data flows continuously, to characterize clinical events. Chronolife has developed a smart wearable that integrates various sensors to monitor physiological data continuously. This data is analyzed by the smartphone application on patient’s phone that uses HOTS technology to conduct data fusion. Chronolife is at the CES (Consumer Electronic Show) this week. Booth 50415 Business France Pavilion , Eureka Park, Sands Expo Convention Center, Venetian Hotel 3355 S Las Vegas Blvd, Las Vegas, NV 89109
Agence Weber Shandwick
email@example.com – +33 (0)1 47 59 56 39